贝伐单抗联合化疗治疗晚期非小细胞肺癌的有效性评价

目的评价贝伐单抗(15mg/kg)联合化疗治疗晚期非小细胞肺癌患者的有效性。方法通过检索PubMed和Cochrane Library数据库,收集了四个随机对照临床试验进行meta分析,有效性的评价指标包括疾病无进展生存时间(PFS)和总生存时间(OS)。结果与对照组相比,贝伐单抗组的患者的疾病进展风险比为0.709(P<0.001),死亡风险比为0.804(P=0.002)。结论对于晚期非小细胞肺癌,采用贝伐单抗(15mg/kg)联合化疗的治疗方法会显著提高患者的PFS和OS。

The Efficacy of Chemotherapy with Bevacizumab for Patients with Advanced Non-Small Cell Lung Cancer: Meta-Analysis from 4 Randomized Clinical Trials

Objective Several randomized clinical studies have evaluated bevacizumab in combination with chemotherapy.We performed this meta analysis to better evaluate the efficacy of chemotherapy with bevacizumab for patients with advanced NSCLC.Methods We searched PubMed,Cochrane Library and abstracts from the proceedings of the American Society of Clinical Oncology(ASCO),and four randomized controlled clinical trials were identified for meta-analysis.The outcomes of efficacy included PFS and OS.Results Compared to chemotherapy alone,the hazard ratio for disease progression of bevacizumab(15 mg/kg)+chemotherapy group is 0.709(P<0.001),the hazard ratio for death 0.804(P=0.002).Conclusion For NSCLC,chemotherapy with bevacizumab will significantly improve patients’ PFS and OS.